

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
9 October 2003 (09.10.2003)

PCT

(10) International Publication Number  
**WO 03/082858 A1**

- (51) International Patent Classification<sup>7</sup>: **C07D 401/12** (74) Agents: CORD, Janet, I. et al.; Ladas & Parry, 26 West 61st Street, New York, NY 10023 (US).
- (21) International Application Number: PCT/US03/09307 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 25 March 2003 (25.03.2003) (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (25) Filing Language: English (71) Applicant (*for all designated States except US*): DR. REDDY'S LABORATORIES LIMITED [IN/IN]; 7-1-27 Ameerpet, Hyderabad 500 016 (IN).
- (26) Publication Language: English (71) Applicant (*for GD only*): CORD, Janet, I. [US/US]; 26 West 61st Street, New York, NY 10023 (US).
- (30) Priority Data: 207/MAS/02 26 March 2002 (26.03.2002) IN (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): REDDY, Manne, Satyanarayana [IN/IN]; 7-1-27 Ameerpet, Hyderabad 500 016 (IN). ESWARAIAH, Sajja [IN/IN]; 7-1-27 Ameerpet, Hyderabad 500 016 (IN). BOLUGODDU, Vijaya, Bhaskar [IN/IN]; 7-1-27 Ameerpet, Hyderabad 500 016 (IN). PINGILI, Ramchandra, Reddy [IN/IN]; 7-1-27 Ameerpet, Hyderabad 500 016 (IN). GANTA, Madhusudhan, Reddy [IN/IN]; 7-1-27 Ameerpet, Hyderabad 500 016 (IN).


**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: CRYSTALLINE FORMS OF RABEPRAZOLE SODIUM

WO 03/082858 A1




(57) Abstract: The present invention relates to novel polymorphic forms of Rabeprazole sodium. The present invention also relates to methods of making polymorphic forms of Rabeprazole sodium. Achipex7 (Rabeprazole sodium) is an inhibitor of the gastric proton pump. It causes dose-dependant inhibition of acid secretion and is useful as an antiulcer agent. The chemical designation of Rabeprazole sodium is 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl] sulfinyl]-1*H*-benzimidazole sodium. It may be represented by Formula (1).

- 1 -

### CRYSTALLINE FORMS OF RABEPRAZOLE SODIUM

The present invention relates to novel polymorphic forms of Rabeprazole sodium. The present invention also relates to methods of making polymorphic forms of Rabeprazole sodium.

5           Achipex<sup>7</sup> (Rabeprazole sodium) is an inhibitor of the gastric proton pump. It causes dose-dependant inhibition of acid secretion and is useful as an antiulcer agent. The chemical designation of Rabeprazole sodium is 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl] sulfinyl]-1H-benzimidazole sodium. It may be represented by Formula (1):



10           U.S. Patent No. 5,045,552 incorporated herein by reference describes the synthesis of Rabeprazole and its sodium salt. Rabeprazole is prepared by oxidizing 2-[{4-(3-methoxypropoxy)-3-methylpyridine-2-yl} methylthio]-1H-benzimidazole with m-chloroperbenzoic acid to afford the Rabeprazole base, which is then converted to its sodium salt by aqueous sodium hydroxide solution.

15           Polymorphism is the occurrence of different crystalline forms of a single compound and it is a property of some compounds and complexes. Thus, polymorphs are distinct solids sharing the same molecular formula, yet each polymorph may have distinct physical properties. Therefore a single compound may give rise to a variety of polymorphic forms where each form has different and distinct physical properties, such as  
20           different solubility profiles, different melting point temperatures and/or different X-Ray diffraction peaks. Since the solubility of each polymorph may vary, identifying the existence of pharmaceutical polymorphs is essential for providing pharmaceuticals with predictable solubility profiles. It is desirable to investigate all solid forms of a drug, including all polymorphic forms, and to determine the stability, dissolution and flow  
25           properties of each polymorphic form. Polymorphic forms of a compound can be distinguished in the laboratory by X-Ray diffraction spectroscopy and by other methods such as, infrared spectrometry.

- 2 -

Crystal forms of Rabeprazole are mentioned in Japanese Patent 2001-39975 and they are designated as crystal I and II. However crystal I is not identified by recognized methods of crystal structure identification such as X-Ray diffraction.

The crystal II of Rabeprazole sodium, however, is discussed in detail and  
5 is characterized by its X-Ray diffraction spectroscopy, Infrared spectrometry and Differential Scanning Colorimetry.

The process for the preparation of crystal II as disclosed in the Japanese Patent specification comprises crystallization of amorphous Rabeprazole sodium or acetone complex of Rabeprazole sodium in one or more solvents selected from ethyl acetate, isopropyl acetate, isobutyl acetate, ethyl propionate, isobutyl propionate and 10 ethyl butyrate.

The X-ray diffractogram for crystal II as in Japanese Patent 2001-39975 is as follows:

2 theta(°)	I/I <sub>0</sub> (%)
19.52	100
17.20	41
26.60	28
20.92	18
18.04	17
24.76	13
21.20	12
14.22	10
17.60	10
25.00	10
29.40	10
28.76	9
27.56	7
27.76	7
12.54	5
13.20	5
24.38	5
28.50	5
34.04	5
13.80	4
22.64	4
24.16	4
30.00	4
31.62	3
12.82	3
34.92	2

- 3 -

2 theta(°)	I/I <sub>o</sub> (%)
25.92	2
11.84	2
8.88	1
9.64	1

The present invention provides for novel crystalline forms of Rabeprazole sodium, which are designated as Form X and Form Y for convenience. Another aspect of the invention is to provide hydrates of Form X and Form Y of Rabeprazole.

5 Another aspect of the present invention is to provide processes for the preparation of the crystalline Form X and Form Y of Rabeprazole sodium. The processes are commercially viable and well-suited for industrial scale up.

#### Brief Description Of Accompanying Drawings

Fig.1 is characteristic X ray powder diffractogram of Form X of  
10 Rabeprazole sodium.

Fig. 2 is Differential Scanning Calorimetry thermogram of Form X of Rabeprazole sodium.

Fig. 3 is characteristic X ray powder diffractogram of Form Y of Rabeprazole sodium.

15 Fig. 4 is Differential Scanning Calorimetry thermogram of Form Y of Rabeprazole sodium.

The present invention provides novel crystalline Form X and Form Y of Rabeprazole sodium. Each of these solid-state forms includes non-solvated and hydrated crystalline forms. The crystalline Form X and Form Y of the present invention may be  
20 characterized by their X Ray powder diffraction patterns. The X-Ray diffraction patterns of Form X and Y of Rabeprazole sodium were measured on a Bruker Axs, D8 Advance Powder X-ray Diffractometer with Cu K alpha-1 Radiation source.

Scan range = 3 - 45° (2 Theta)

Scan speed = step size 0.02°, time for step is 0.4 seconds.

25 Sampling time : Scan time : 14:0.40 min  
 Scan mode : Continuous  
 Reflection : Geometry is Reflection (Not transmission)  
 Scan type : Locked coupled  
 Voltage = 45 KV,

- 4 -

Current = 35 mA

Crystalline Form X has X-ray powder diffraction pattern essentially as shown in the Table 1. The X-ray powder diffraction pattern is expressed in term of the  $2\theta$ , and relative intensities (cps).

5

**TABLE 1**

<b>2θ(°)</b>	<b>Intensity (cps)</b>
5.13	1184
6.606	225
20.01	215
23.469	193
8.569	169
12.923	154
20.539	135
22.177	131
24.81	125
10.565	125
12.161	116
9.353	113
18.173	99.3
17.309	85.3
14.864	81.3
25.494	75.3
16.372	69.9
14.414	60.2
7.244	57.5
19.072	56.2

The present invention also provides Form X of Rabeprazole sodium that is characterized by its X Ray powder diffraction substantially as depicted in Figure 1.

10 The present invention also provides the Differential Scanning Calorimetry thermogram of Form X of Rabeprazole sodium. The Differential Scanning Calorimetry thermogram exhibits a significant endo-exo pattern at 154.62°C and 214.65°C.

The present invention also provides Differential Scanning Calorimetry thermogram of Form X of Rabeprazole sodium substantially as depicted in Figure 2.

15 The present invention also provides melting range (capillary method) of crystalline Form X at 140-150°C.

Accordingly the present invention also provides a process for the preparation of Form X of Rabeprazole sodium, which comprises the steps of:

- 5 -

- a) dissolving 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1*H*-benzimidazole in a solvent comprising C<sub>1</sub>-C<sub>4</sub> alkanol solution of a sodium hydroxide or a mixture thereof, followed by distillation off of the solvent;
  - 5 b) adding a chlorinated C<sub>1</sub>-C<sub>3</sub> hydrocarbon solvent or a mixture;
  - c) distilling the residual C<sub>1</sub>-C<sub>4</sub> alkanol of a sodium hydroxide azeotropically under reduced pressure from the reaction solution of b);
  - d) adding a chlorinated C<sub>1</sub>-C<sub>3</sub> hydrocarbon solvent and an C<sub>5</sub>-C<sub>10</sub> alkane or a C<sub>5</sub>-C<sub>10</sub> cyclic alkane or mixtures thereof; accompanied by stirring; and isolating Form X of Rabeprazole sodium.
- 10 The 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1*H*-benzimidazole may be prepared by any process. Preferably, the 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1*H*-benzimidazole is prepared as in the Reference Example.

15 The Form X of Rabeprazole sodium may be isolated using methods such as filtration or centrifugation.

The C<sub>1</sub>-C<sub>4</sub> alkanol of a sodium hydroxide may be selected from methanolic sodium hydroxide, ethanolic sodium hydroxide or isopropanolic sodium hydroxide or mixtures thereof, preferably, methanolic sodium hydroxide.

20 The C<sub>1</sub>-C<sub>4</sub> alkanol of a sodium hydroxide may be prepared by mixing the C<sub>1</sub>-C<sub>4</sub> alkanol with sodium hydroxide *in situ*.

The chlorinated C<sub>1</sub>-C<sub>3</sub> hydrocarbon solvent may be selected from dichloromethane, dichloroethane, trichloroethane, tetrachloroethane, dichloropropane, dichloropropane, chloroform or carbon tetrachloride, preferably dichloromethane.

25 The alkane may be selected from pentane, hexane, heptane, petroleum ether, octane, i-octane, nonane, or decane or mixtures thereof, preferably petroleum ether.

The cyclic alkane may be selected from cyclopentane, cyclohexane, or cycloheptane or mixtures thereof, preferably cyclohexane.

30 In step a) the preferred ratio of 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1*H*-benzimidazole to the C<sub>1</sub>-C<sub>4</sub> alkanol of a sodium hydroxide is 1:2 w/v (i.e. 1 gram of 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1*H*-benzimidazole to 2 ml of the C<sub>1</sub>-C<sub>4</sub> alkanol of a sodium hydroxide).

In step b) the ratio of residual mass of step a) to chlorinated C<sub>1</sub>-C<sub>3</sub>

- 6 -

hydrocarbon is 1:1-10 w/v, preferably 1:2 w/v.

In step d) the ratio of chlorinated hydrocarbon solvent to alkane and/or cyclic alkane is 1:5-15 v/v; preferably 1:5-10 v/v and more preferably 1:5 v/v.

Another aspect of this invention is to provide crystalline Form Y of

- 5 Rabeprazole. Form Y of Rabeprazole has X-ray powder diffraction pattern essentially as shown in the Table 2. The X-ray powder diffraction pattern is expressed in terms of the  $2\theta$ , the relative intensities (cps).

TABLE 2

$2\theta(^{\circ})$	Intensity (cps)
5.61	1635
19.442	546
18.816	329
7.725	285
7.207	242
9.649	235
10.352	219
16.899	186
24.943	162
16.418	104
14.546	103
11.231	77.0

- 10 The present invention also provides Form Y of Rabeprazole sodium that is characterized by its X Ray powder diffraction substantially as depicted in Figure 3.

The present invention also provides the Differential Scanning Calorimetry thermogram of Form Y of Rabeprazole sodium. The Differential Scanning Calorimetry thermogram exhibits a significant endo-exo pattern at 182.61°C and 215.57°C.

- 15 The present invention also provides Differential Scanning Calorimetry thermogram of Form Y of Rabeprazole substantially as depicted in Figure 4.

Accordingly the present invention also provides a process for the preparation of Form Y of Rabeprazole sodium, which comprises the steps of:

- a) dissolving 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole in a solvent comprising C<sub>1</sub>-C<sub>4</sub> alkanol of sodium hydroxide or mixtures thereof, followed by distilling the solvent from the reaction solution;
- b) optionally adding chlorinated a C<sub>1</sub>-C<sub>3</sub> hydrocarbon solvent to the

- 7 -

residual mass obtained in step a);

- c) distilling the residual C<sub>1</sub>-C<sub>4</sub> alkanol of sodium hydroxide azeotropically under reduced pressure from the reaction solution of step b);
- d) adding to the residue obtained in step c) either a C<sub>3</sub>-C<sub>5</sub> straight or branched chain alcohol and an ether solvent having a C<sub>1</sub>-C<sub>4</sub> straight or branched carbon chain; and isolating Form Y of Rabeprazole sodium.

The 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole may be prepared by any process. Preferably, the 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole is prepared as in the Reference Example.

The Form Y of Rabeprazole sodium may be isolated using methods such as filtration or centrifugation.

The C<sub>1</sub>-C<sub>4</sub> alkanol of a sodium hydroxide may be selected from methanolic sodium hydroxide, ethanolic sodium hydroxide or isopropanolic sodium hydroxide or mixtures thereof, preferably, methanolic sodium hydroxide.

The C<sub>1</sub>-C<sub>4</sub> alkanol of a sodium hydroxide may be prepared by mixing the C<sub>1</sub>-C<sub>4</sub> alkanol with sodium hydroxide *in situ*.

The chlorinated C<sub>1</sub>-C<sub>3</sub> hydrocarbon solvent may be selected from dichloromethane, dichloroethane, trichloroethane, dichloropropane, tetrachloroethane, dichloropropane, chloroform or carbon tetrachloride, preferably dichloromethane.

The C<sub>3</sub>-C<sub>5</sub> straight or branched chain alcohol may be selected from n-propanol, n-butanol, 2-butanol, or tert. Butanol, preferably n-butanol.

The ether solvent having a C<sub>1</sub>-C<sub>4</sub> straight or branched carbon chain may be selected from diethyl ether, methyl ethyl ether, diisobutyl ether, ditertiary Butyl ether or tertiary Butyl methyl ether.

In step a) the preferred ratio of 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole to the C<sub>1</sub>-C<sub>4</sub> alkanol of a sodium hydroxide is 1:2 w/v (i.e. 1 gram of 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole to 2 ml of the C<sub>1</sub>-C<sub>4</sub> alkanol of a sodium hydroxide).

In step b) the ratio of residual mass to chlorinated C<sub>1</sub>-C<sub>3</sub> hydrocarbon is 1:1-10 w/v, preferably 1:2 w/v.

In step d) the ratio of alcohol to ether solvent is 1:10-20 v/v, preferably

- 8 -

1:15-20 v/v, more preferably 1:16 v/v.

2-[(4-3-methoxypropoxy)-3-methylpyridine-2-yl] methylthio]-1H-benzimidazole (I) can be prepared using the methods disclosed in the U.S. Patent 5,045,552.

5        The oxidation step of (I) maybe carried out in solvents such as C<sub>1</sub>-C<sub>5</sub> straight or branched chain alcohols or mixtures thereof viz., methanol, ethanol, n-propanol, 2-propanol, n-butanol, tertiary butanol and n-pentanol or haloalkane solvents viz., chloroform, dichloromethane and dichloroethane or aromatic hydrocarbon solvents viz., benzene, toluene and exylene or cyclic ether solvents viz., tetrahydrofuran and dioxane or polar organic solvents viz., dimethyl formamide dimethyl sulfoxides, preferably a mixture of chloroform and dimethylsulfoxide wherein the ratio of (I) to chloroform is 1:3-10 w/v and the ratio of (I) to dimethyl sulfoxide is 1:1-3 w/v, in presence of oxidizing agents such as hydrogen peroxide, peracetic acid, 3-chloroperbenzoic acid, sodium hypo chlorite or sodium hypobromite, preferably 3-chloroperbenzoic acid wherein the ratio of (I) to 3-chloroperbenzoic acid is 1:0.5-1.5 w/w which is dissolved in one of the solvents recited above in chloroform. The temperature at which the oxidation can carried out can vary from -40°C to boiling point of the solvent used, preferably 10 to 15°C till the reaction is substantially complete.

10      Thereafter 10-15% w/v aqueous alkaline solution hydroxide, potassium hydroxide, sodium carbonate and potassium carbonate, preferably aqueous solution of sodium hydroxide is added to the reaction mixture. The pH of the reaction mixture is adjusted to 9-12 using an acid such as acetic acid, hydrochloric acid or hydrobromic acid. The resultant biphasic system thus obtained is separated and the organic layer is extracted with 1-5% w/v aqueous alkaline solution recited above, preferably aqueous solution of sodium hydroxide. This alkaline extract is diluted with a mixture of halo alkane solvent as recited above, preferably chloroform wherein the ratio of (I) to chloroform is 1:1-3 w/v and an alcohol or a mixture of alcohols as recited above, preferably methanol wherein the ratio of (I) to methanol is 1:1-3 w/v.

15      Then the pH of the mass is again adjusted to 9-12 with an acid as recited above, and the organic layer separated. To the separated organic layer is now added an ether solvent having C<sub>1</sub>-C<sub>4</sub> straight or branched chain carbon atoms viz., diethyl ether, methyl ethyl ether, diisobutyl ether, ditertiary butyl ether or tertiary butyl methyl wherein

- 9 -

the ratio of (I) to ether is 1:3-7 w/v. The reaction mixture is then stirred till the complete crystallization, at a temperature of 0-25°C, preferably at 0-5°C and subjected to filtration.

The resultant solid is then dissolved in a mixture of 10 to 20% w/v aqueous alkalkine solution as recited above, preferably aqueous solution of sodium 5 hydroxide and an alcohol or a mixture of alcohols as recited above, preferably methanol. The pH is adjusted to 9-10, with an acid as described above, at 0-25°C, preferably 0-5°C until complete crystallization. The 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridine]-methyl]sulfinyl]-1H-benzimidazole thus obtained is filtered and dried.

The crystalline forms of Rabeprazole sodium of the present invention are 10 also high melting solids with residual solvents within permissible limits and are very well suited for formulation.

The present invention also envisages pharmaceutical compositions prepared using Form X or Form Y of Rabreprazole (2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl] sulfinyl]-1H-benzimidazole sodium) and a physiologically 15 acceptable carrier, diluent, excipient, additive, filler, lubricant, binder, stabilizer, solvent or solvate.

The pharmaceutical composition may be in a form normally employed, such as tablets, capsules, lozenges, powders, syrups, solutions, suspensions, ointments, dragees and the like, may contain flavourants, sweetners, etc. in suitable solid or liquid 20 carriers or diluents, or in suitable sterile media to form injectable solutions or suspensions. Such compositions typically contain from 1 to 25%, preferably 1 to 15% by weight of active ingredient, the remainder of the composition being one or more of a pharmaceutically acceptable carrier, diluent, excipient, additive, filler, lubricant, binder, stabilizer, solvent or solvate.

25 The Form X or Form Y of Rabreprazole (2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl] sulfinyl]-1H-benzimidazole sodium can be administered to mammals, including man, via either oral, nasal, pulmonary, transdermal or parenteral, rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic solution or an ointment. Administration by the oral route is preferred.

30 Dosage is in the range or about 0.01 to about 100 mg/kg body weight of the subject per day or preferably about 0.01 to about 100 mg/kg body weight of the subject per day or preferably about 0.01 to about 30 mg/kg body weight per day

- 10 -

administered singly or as a divided dose. However, the optimum dosage for the individual subject being treated will be determined by the person responsible for treatment, generally smaller doses being administered initially and thereafter increments made to determine the most suitable dosage.

5            Suitable pharmaceutically acceptable carriers include solid fillers or diluents and sterile aqueous or organic solutions. The active ingredient will be present in such pharmaceutical compositions in the amounts sufficient to provide the desired dosage in the range as described above. Thus, for oral administration, the compound can be combined with a suitable solid or liquid carrier or diluent to form capsules, tablets,  
10        powders, syrups, solutions, suspensions and the like. The pharmaceutical compositions, may, if desired, contain additional components such as flavourants, sweeteners, excipients and the like. For parenteral administration, the compound can be combined with sterile aqueous or organic media to form injectable solutions or suspensions. For example, solutions in sesame or peanut oil, aqueous solutions of water-soluble pharmaceutically-  
15        acceptable acid addition salts or salts with base of the compounds. Aqueous solutions with the active ingredient dissolved in polyhydroxylated castor oil may also be used for injectable solutions. The injectable solutions prepared in this manner can then be administered intravenously, intraperitoneally, subcutaneously, or intramuscularly, with intramuscular administration being preferred in humans.

20        For nasal administration, the preparation may contain the compound of the present invention dissolved or suspended in a liquid carrier, in particular an aqueous carrier, for aerosol application. The carrier may contain additives such as solubilizing agents, such as propylene glycol, surfactants, absorption enhancers such as lecithin (phosphatidylcholine) or cyclodextrin or preservatives such as parabenes.

25        Tablets, dragees or capsules having talc and/or a carbohydrate carried binder or the like are particularly suitable for any oral application. Preferably, carriers for tablets, dragees or capsules include lactose, corn starch and/or potato starch. A syrup or elixir can be used in cases where a sweetened vehicle can be employed. An effective amount means that amount of a drug or pharmaceutical agent that will elicit the biological  
30        or medical response of a tissue, system, human or animal sought.

The compositions may be prepared by methods known to those in the pharmaceutical field.

- 11 -

Form X and Form Y of Rabeprazole sodium show better chemical stability such as thermo stability and light stability as compared to prazoles such as panto prazole sodium and omeprazole sodium.

- Fig-1 is characteristic X-ray powder diffraction pattern of Form X of 2-
- 5 [[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl] sulfinyl]-1H-benzimidazole sodium (Rabeprazole sodium).

Vertical axis: Intensity (CPS); Horizontal axis: 2 $\theta$  values (in degrees) obtained are 5.13, 6.606, 7.244, 8.569, 9.353, 10.565, 12.161, 12.923, 14.414, 14.864, 16.372, 17.309, 18.173, 19.072, 20.01, 20.539, 22.177, 23.469, 24.81 and 25.494.

- 10 Fig-2 is Differential Scanning Calorimetry thermogram of Form X of 2- [[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl] sulfinyl]-1H-benzimidazole sodium (Rabeprazole sodium). The Differential Scanning Calorimetry thermogram exhibits a significant endo-exo pattern at 154.62°C and 214.65°C. The heating rate for the DSC is 5 deg./minute.

- 15 Fig-3 is characteristic X-ray powder diffraction pattern of Form Y of 2- [[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl] sulfinyl]-1H-benzimidazole sodium (Rabeprazole sodium).

- Vertical axis: Intensity (CPS); Horizontal axis: 2 $\theta$  (degrees). The significant 2 $\theta$  values (in degrees) obtained are 5.61, 7.207, 7.725, 9.649, 10.352, 11.231, 20 14.546, 16.418, 16.899, 18.816, 19.442 and 24.943.

- 25 Fig-4 is Differential Scanning Colorometry thermogram of Form Y of 2- [[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl] sulfinyl]-1H-benzimidazole sodium (Rabeprazole sodium). The Differential Scanning Calorimetry thermogram exhibits a significant endo-exo pattern at 182.61°C and 215.57°C.

- The heating rate for the DSC is 5 deg./minute.

The present invention is illustrated by the following examples, which are not intended to limit the effective scope of the claims.

#### Reference Example

- 2-[{4-(3-methoxypropoxy)-3-methylpyridine-2-yl}methylthio] -1H-benzimidazole (prepared as per example 90 of the U.S. Patent No. 5,045,552) (100 grams, 30 0.29 moles) is added to a mixture of chloroform (500 ml) and dimethylsulfoxide (200 ml) and the reaction mixture is cooled to -10 to -15°C. 3-chloroperbenzoic acid (60 grams,

- 12 -

0.24 moles) is dissolved in chloroform (500 ml), and added to the above solution at -10 to -15°C for about 1-12 hours and the reaction mixtures maintained at the same temperature for 30 minutes. Thereafter 12.8% w/v aqueous sodium hydroxide solution (500 ml) is added to the reaction mixture. The pH of the reaction mixture is adjusted to 9.5 to 10.0  
5 with acetic acid. Of the biphasic system thus obtained the organic layer is separated and then extracted with 1.6% w/v aqueous sodium hydroxide solution (500 ml). Further the sodium hydroxide extract is diluted with a mixture of chloroform (140 ml) and methanol (100 ml). Then the pH of the mass is again adjusted to 9.5 to 10.0 with acetic acid and the organic layer separated again. To the separated organic layer is now added tert.butyl  
10 methyl ether (440 ml). The reaction mixture is stirred for about 1-12 hours at a temperature of 0-5°C and subjected to filtration. The residue is dissolved in a mixture of 10% w/v aqueous sodium hydroxide solution (100 ml) and methanol (65 ml). The pH is adjusted to 9.0 to 9.5 with acetic acid at 10-15°C and further stirred for 12 hours followed by filtration. The wet material is then dissolved in dichloromethane (130 ml) and the  
15 water layer separated where after the solution is added to tert.butyl methyl ether (260 ml), stirred at a temperature of 0-5°C for 1-2 hours. The 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl] sulfinyl]-1H-benzimidazole thus obtained is filtered and dried.

#### Example 1

20                   Preparation Of Crystalline Form-X Of Rabeprazole Sodium  
2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl] sulfinyl]-1H-benzimidazole (obtained as per reference example) (50.0 grams, 0.139 moles) is dissolved in a mixture of sodium hydroxide (7.5 grams, 0.187 moles) and methanol (100.0 ml) and stirred at ambient temperature. The reaction solution is filtered through hi-flow and  
25 washed with methanol (50.0 ml). Methanol from the filtrate is distilled off under high vacuum. The reaction mass is cooled to ambient temperature followed by addition of dichloromethane (100.0 ml) accompanied by distillation to remove traces of methanol. Dichloromethane (50.0 ml) and petroleum ether (100.0 ml) is then added to the residual mass, which is then stirred at 25-30°C for about 6-8 hours. The solid that is obtained  
30 further diluted with petroleum ether (150 ml) and stirred at 25-30°C for about 6-8 hours. The precipitated solid is filtered and washed with petroleum ether (100.0 ml) and dried at 50-60°C for 12 hours to afford the desired Form X of Rabeprazole sodium (Weight: 50.4

- 13 -

grams, 94.9%).

The X-ray Diffraction Pattern, Differential Scanning Calorimetry thermogram of Form X of Rabeprazole sodium obtained in above example is in accordance with Figure 1 and 2 respectively.

5

### Example 2

#### Preparation Of Crystalline Form-Y Of Rabeprazole Sodium

2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl] sulfinyl]-1H-benzimidazole (obtained as per reference example) (750.0 grams, 2.089 moles) is dissolved in a mixture of sodium hydroxide (112.5 grams, 2.8125 moles) and methanol 10 (1500.0 ml) and stirred at ambient temperature. The reaction solution is filtered through hi-flow and washed with methanol (750.0 ml). Methanol from the filtrate is distilled off under high vacuum. The reaction mass is cooled to ambient temperature followed by addition of dichloromethane (1500.0 ml) accompanied by distillation to remove traces of methanol. The reaction mass is cooled to ambient temperature and n-butanol (375.0 ml) 15 and tertiary butyl methyl ether (6.0 lit) is added to the residual mass which is stirred at 25-30°C for 6-8 hours. The reaction mixture is further cooled to 5-15°C and then stirred for another 3-5 hours. The solid is thus obtained is filtered and washed with tertiary butyl methyl ether (1500.0 ml) and dried at 50-60°C for 7 hours to afford the desired crystalline Form Y of Rabeprazole sodium (Weight:725.0 grams 91.1%).

20

The X-ray Diffraction Pattern, Differential Scanning Calorimetry thermogram of Form Y of Rabeprazole sodium obtained in the example is in accordance with Figure 3 and 4 respectively.

- 14 -

CLAIMS

1. A crystalline Form X of 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl] sulfinyl]-1*H*-benzimidazole (Form X of Rabeprazole sodium) or hydrates thereof.
- 5 2. The crystalline Form X of Rabeprazole sodium of claim 1 having X-ray powder diffraction pattern with peaks at about 5.13, 6.606, 7.244, 8.569, 9.353, 10.565, 12.161, 12.923, 14.414, 14.864, 16.372, 17.309, 18.173, 19.072, 20.01, 20.539, 22.177, 23.469, 24.81 and 25.494 (degrees 2 theta).
- 10 3. The crystalline Form X of Rabeprazole sodium of claim 1 having an X-ray powder diffraction pattern substantially as depicted in Figure 1.
4. The crystalline Form X of Rabeprazole sodium of claim 1 having a differential scanning calorimetry thermogram which exhibits a significant endo-exo pattern at 154.62°C and 214.65°C.
5. The crystalline Form X of Rabeprazole sodium of claim 1 having 15 characteristic Differential Scanning Calorimetry thermogram substantially as depicted in Figure 2.
6. The crystalline Form X of Rabeprazole sodium of claim 1 having melting range of 140-150°C.
7. A process for preparing Form X of 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl] sulfinyl]-1*H*-benzimidazole sodium (Form X of Rabeprazole sodium), which comprises:
  - a) dissolving 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl] sulfinyl]-1*H*-benzimidazole in a C<sub>1</sub>-C<sub>4</sub> alkanol of sodium hydroxide or mixtures thereof, distilling the solvent from the reaction solution;
  - 25 b) adding chlorinated C<sub>1</sub>-C<sub>3</sub> hydrocarbon solvent or a mixture thereof to the residual mass obtained in step a)
  - 3) distilling the residual solvent of C<sub>1</sub>-C<sub>4</sub> alkanol of sodium hydroxide azeotropically under reduced pressure from the reaction solution of b);
  - d) adding a chlorinated C<sub>1</sub>-C<sub>3</sub> hydrocarbon solvent and a C<sub>5</sub>-C<sub>10</sub> alkane solvent or C<sub>5</sub>-C<sub>10</sub> cyclic alkane; or mixtures thereof; accompanied by stirring, and
  - 30 5) isolating Form X 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl] sulfinyl]-1*H*-benzimidazole sodium.

- 15 -

8. A crystalline Form Y of 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl] sulfinyl]-1*H*-benzimidazole sodium (Form Y of Rabeprazole sodium) or hydrates thereof.
9. The crystalline Form Y of Rabeprazole sodium of claim 8, having an X-ray powder diffraction pattern with peaks at about 5.61, 7.207, 7.725, 9.649, 10.352, 11.231, 14.546, 16.418, 16.899, 18.816, 19.442 and 24.943 (degrees 2 theta).
10. The crystalline Form Y of Rabeprazole sodium of claim 8, having an X-ray powder diffraction pattern substantially as depicted in Figure 3.
11. The crystalline Form Y of Rabeprazole sodium of claim 8, having a differential scanning calorimetry thermogram which exhibits a significant endo-exo pattern at 182.61°C and 215.57°C.
12. The crystalline Form Y of Rabeprazole sodium of claim 8, having characteristic Differential Scanning Calorimetry thermogram substantially as depicted in Figure 4.
13. The crystalline Form Y of claim 7, having melting range of 160-170°C.
14. A process for preparing Form Y of 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl] sulfinyl]-1*H*-benzimidazole sodium (Form Y of Rabeprazole sodium), which comprises:
  - a) dissolving 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl] sulfinyl]-1*H*-benzimidazole in C<sub>1</sub>-C<sub>4</sub> alkanol of sodium hydroxide or mixtures thereof, distilling the solvent from the reaction solution;
  - b) optionally adding a chlorinated C<sub>1</sub>-C<sub>3</sub> hydrocarbon solvent to the residual mass obtained in step a);
  - c) distilling the residual solvent of C<sub>1</sub>-C<sub>4</sub> alkanol of sodium hydroxide azeotropically under reduced pressure from the reaction solution of b);
  - d) adding to the residue obtained in step c) either a C<sub>3</sub>-C<sub>5</sub> straight or branched chain alcohol and an ether solvent, or mixtures thereof; accompanied by stirring, and
  - e) isolating Form Y of 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl] sulfinyl]-1*H*-benzimidazole sodium.
15. A composition comprising a crystalline Form X of 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl] sulfinyl]-1*H*-benzimidazole sodium or hydrates thereof

- 16 -


according to any one of claims 8 to 1-6 and a physiologically acceptable carrier, diluent, excipient, additive, filler, lubricant, binder, stabilizer, solvent or solvate.

16. A composition comprising a crystalline Form Y of 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl] sulfinyl]-1*H*-benzimidazole sodium or hydrates thereof

5 according to any one of claims 8 to 13 and a physiologically acceptable carrier, diluent, excipient, additive, filler, lubricant, binder, stabilizer, solvent or solvate.


1/4

FIG. 1




SUBSTITUTE SHEET (RULE 26)

2/4

**FIG. 2****SUBSTITUTE SHEET (RULE 26)**

3/4

**FIG. 3**  
Thermal Analysis Data




SUBSTITUTE SHEET (RULE 26)

4/4

**FIG. 4**

## Thermal Analysis Data



SUBSTITUTE SHEET (RULE 26)

## INTERNATIONAL SEARCH REPORT

International	Application No
PCT/US 03/09307	

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D401/12

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JP 2001 039975 A (EISAI CO., LTD., JAPAN) 13 February 2001 (2001-02-13) cited in the application the whole document ----	1-14
X	NOCHI, SHIGEHARU ET AL: "Preparation and absolute configurations of optical isomers of sodium 2-'4-(3-methoxypropoxy)-3-methylpyridin-2-yl!methylsulfinyl!-1H- benzimidazole (E3810)" CHEMICAL & PHARMACEUTICAL BULLETIN (1996), 44(10), 1853-1857 , XP009014313 the whole document ----	1-14

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

28 July 2003

Date of mailing of the international search report

05/08/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Von Daacke, A

## INTERNATIONAL SEARCH REPORT

Internal Application No  
PCT/US 03/09307

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	EP 1 306 375 A (TAKEDA CHEMICAL INDUSTRIES LTD) 2 May 2003 (2003-05-02) * Examples * page 2, line 15-42 & WO 02 012225 A (TAKEDA) 14 February 2002 (2002-02-14) ---	1-14
A	WO 90 06925 A (HAESSLER AB) 28 June 1990 (1990-06-28) example 2 ---	1-14
A	WO 90 06926 A (HAESSLER AB) 28 June 1990 (1990-06-28) example 2 -----	1-14

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

Internat	Application No
PCT/US	03/09307

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
JP 2001039975	A 13-02-2001	NONE	
EP 1306375	A 02-05-2003	AU 762101 A CA 2417311 A1 EP 1306375 A1 WO 0212225 A1 JP 2002114779 A	18-02-2002 27-01-2003 02-05-2003 14-02-2002 16-04-2002
WO 9006925	A 28-06-1990	AT 110723 T AT 127799 T AU 639429 B2 AU 4813290 A AU 634741 B2 AU 4817590 A BG 60101 A3 BG 60102 A3 CA 2005980 A1 CA 2005986 A1 CN 1043713 A ,B CN 1043937 A ,B CS 8907343 A3 DD 296078 A5 DD 296079 A5 DE 68917937 D1 DE 68917937 T2 DE 68924273 D1 DE 68924273 T2 DK 122191 A DK 122291 A EG 19302 A EG 19303 A EP 0449935 A1 EP 0449940 A1 FI 954768 A GR 89100833 A ,B GR 89100838 A ,B HR 920831 A1 HU 57202 A2 HU 57204 A2 HU 205927 B IE 894048 L IE 64199 B1 IL 92799 A JP 2793905 B2 JP 4502460 T JP 2793906 B2 JP 4502461 T LT 1721 A ,B LT 1726 A ,B LV 10267 A ,B LV 10187 A ,B NO 912414 A ,B, NO 912415 A ,B, NZ 231872 A NZ 231874 A PH 27446 A	15-09-1994 15-09-1995 29-07-1993 10-07-1990 04-03-1993 10-07-1990 15-10-1993 15-10-1993 22-06-1990 22-06-1990 11-07-1990 18-07-1990 15-01-1992 21-11-1991 21-11-1991 06-10-1994 05-01-1995 19-10-1995 15-02-1996 24-06-1991 24-06-1991 30-11-1994 30-11-1994 09-10-1991 09-10-1991 06-10-1995 15-03-1991 15-03-1991 31-12-1995 28-11-1991 28-11-1991 22-06-1990 12-07-1995 25-01-1994 03-09-1998 07-05-1992 03-09-1998 07-05-1992 25-07-1995 25-07-1995 20-10-1994 20-10-1994 06-08-1991 06-08-1991 26-03-1992 26-05-1992 02-07-1993
WO 9006926	A 28-06-1990	AT 110379 T	15-09-1994

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/09307

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9006926	A	AU 636866 B2	13-05-1993
		AU 4817690 A	10-07-1990
		CA 2005987 A1	22-06-1990
		CN 1043714 A ,B	11-07-1990
		DD 296077 A5	21-11-1991
		DE 68917738 D1	29-09-1994
		DE 68917738 T2	22-12-1994
		DK 122391 A	24-06-1991
		EP 0451188 A1	16-10-1991
		GR 89100834 A ,B	15-03-1991
		HU 57203 A2	28-11-1991
		IE 64850 B1	06-09-1995
		IL 92797 A	29-12-1994
		JP 2793907 B2	03-09-1998
		JP 4502462 T	07-05-1992
		LT 1722 A ,B	25-07-1995
		LV 10268 A ,B,	20-10-1994
		NO 912415 A ,B,	06-08-1991
		NO 912416 A ,B,	31-07-1991
		PH 27257 A	04-05-1993
		PT 92647 A ,B	29-06-1990
		RO 110496 B1	30-01-1996
		SE 8804628 A	22-12-1988
		WO 9006926 A1	28-06-1990
		RU 2070199 C1	10-12-1996
		US 5019584 A	28-05-1991
		YU 242589 A1	30-04-1991
		ZA 8909796 A	29-08-1990

THIS PAGE BLANK (USPTO)